MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
384.32
+16.52
+4.49%
After Hours: 383.80 -0.52 -0.14% 19:57 02/06 EST
OPEN
369.99
PREV CLOSE
367.80
HIGH
385.12
LOW
368.90
VOLUME
3.84M
TURNOVER
--
52 WEEK HIGH
385.12
52 WEEK LOW
255.23
MARKET CAP
206.95B
P/E (TTM)
27.01
1D
5D
1M
3M
1Y
5Y
1D
Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More
Seeking Alpha · 13h ago
Amgen (AMGN) Receives a Buy from Argus Research
TipRanks · 22h ago
Dividend Champion, Contender, And Challenger Highlights: Week Of February 8
Seeking Alpha · 1d ago
$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Benzinga · 1d ago
P/E Ratio Insights for Amgen
Benzinga · 1d ago
Dow smashes 50,000 and here’s how all 30 stocks rank according to SA Quant Ratings
Seeking Alpha · 1d ago
Dow tops 50,000 for the first time as the blue-chip rally accelerates
Seeking Alpha · 1d ago
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder
Benzinga · 1d ago
More
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.